ArticleACS omega2026
Comprehensive Quality Assessment of Atractylodis macrocephalae Rhizoma Between Standardized Bases and Retail Market Samples in Pan'an County.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a widely used herbal medicine, the quality of Atractylodis macrocephalae Rhizoma (AMR) is significantly influenced by cultivation practices. However, systematic evaluations comparing the quality of AMR derived from different supply chain sources remain insufficient. This two-year study, conducted in the Daodi region of Pan'an County, Zhejiang Province, comprehensively evaluated AMR samples from five standardized planting bases and five open market retail markets. Assessment parameters included basic quality indicators (moisture, total ash, and extractives), characteristic components (atractylenolides I, II, and III, atractylodin, and atractylon), and safety indicators (pesticide residues). The results showed that moisture (6.70%-14.94%) and total ash (3.19%-4.74%) levels in all samples met the requirements of the Chinese Pharmacopoeia (2020 edition). The extractives content ranged from 27.85% to 53.49%, with four retail batches falling below the pharmacopoeial threshold (35.0%). Comprehensive evaluation using violin plots and radar charts revealed that samples from standardized planting bases were generally superior to market samples in characteristic component contents. In terms of safety, pesticide residue levels in standardized base samples were significantly lower than those in retail market samples. These findings demonstrate that the standardized cultivation not only ensures the intrinsic quality of AMR but also reduces safety risks related to pesticide residues. This work provides a scientific basis for strengthening AMR quality control and promoting standardized farming practices, thereby supporting clinical safety and high-quality development of the traditional Chinese medicine industry. Future cost-effectiveness analyses are warranted to comprehensively evaluate the economic viability of standardized cultivation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.